

WE CLAIM :

1. Fexofenadine hydrochloride in an amorphous form.
2. A pharmaceutical composition containing a therapeutically effective amount of the amorphous form of claim 1 together with one or more pharmaceutical carriers or excipients.
3. A process for the preparation of fexofenadine hydrochloride in an amorphous form which comprises dissolving crystalline fexofenadine hydrochloride in a suitable solvent or dissolving fexofenadine base in a suitable solvent and adding a suitable solvent containing hydrogen chloride and recovering fexofenadine hydrochloride from said solution by spray drying or freeze drying technique.
4. The process of claim 3, wherein suitable solvent is selected from the group consisting of lower alkanol, ester, ketone, chlorinated solvent and mixtures thereof.
5. The process of claim 4, wherein lower alkanol includes primary, secondary and tertiary alcohols having from one to six carbon atoms.
6. The process of claim 5, wherein said lower alkanol is selected from the group consisting of methanol, ethanol, n-propanol, isopropanol or n-butanol and mixtures thereof.
7. The process of claim 6, wherein the solvent is methanol, ethanol or isopropanol.
8. The process of claim 4, wherein the ester solvent is selected from ethyl acetate or n-butyl acetate.

9. The process of claim 4, wherein the ketone solvent is acetone, methylethyl ketone, 2-butanone, 4-methylpentan-2-one.
10. The process of claim 4, wherein the chlorinated solvent is chloroform, dichloromethane or carbontetrachloride.
11. The process of claim 3, wherein fexofenadine hydrochloride in an amorphous form is isolated from said solution by spray drying.
12. The process of claim 3, wherein the spray drying is effected in the presence of an inert gas.
13. The process of claim 3, wherein fexofenadine hydrochloride in an amorphous form is isolated from said solution by freeze drying.